Drugs.com

APRIL 30, 2025

2024, GlaxoSmithKline withdrew Flovent from the market. WEDNESDAY, April 30, 2025 More children stopped using steroid inhalers to control their asthma after a manufacturer discontinued a popular inhaler, a new study says.In The inhaler was c.

Marketing 242

Marketing Production 242

Drugs.com

OCTOBER 10, 2023

They are marketed with. MONDAY, Oct. 9, 2023 -- Flavoring added to small, cheap cigars is making these the second-most popular tobacco product among youth, a new report shows. The report comes as federal regulators prepare to bar flavored cigars.

Marketing 264

Marketing Regulations Production 264

BioPharma Drive: Drug Pricing

AUGUST 8, 2023

The Indianapolis drugmaker is now worth more than $500 billion, higher than any other pharmaceutical company, as analysts project lucrative markets for its obesity and Alzheimer's drugs.

Marketing 246

Marketing Pharmaceutical Companies Drugs Pharmaceuticals 246

BioPharma Drive: Drug Pricing

JULY 17, 2023

Meet the pharma marketer of the future, primed for personalization and powered by technology.

Marketing 246

Marketing 246

BioPharma Drive: Drug Pricing

AUGUST 14, 2023

Meet the pharma marketer of the future, primed for personalization and powered by technology.

Marketing 246

Marketing 246

Drugs.com

JULY 19, 2024

FRIDAY, July 19, 2024 -- The U.S. Food and Drug Administration on Thursday authorized the sale of the country's best-selling e-cigarette.The agency's decision only applies to several tobacco-flavored versions of the reusable product, sold as Vuse.

Marketing 264

Marketing FDA Production Drugs 264

BioPharma Drive: Drug Pricing

JANUARY 17, 2024

The offering is the fifth outlined by a biotech startup this month, suggesting companies are becoming more willing to gauge investors’ appetite for new stock offerings.

Marketing 315

Marketing 315

BioPharma Drive: Drug Pricing

APRIL 25, 2025

The drug, being developed for a rare genetic disorder and currently under review in the U.S., is seen by some investors as critical to Biohaven’s future.

Marketing 270

Marketing Drugs 270

Drugs.com

FEBRUARY 21, 2024

WEDNESDAY, Feb. 21, 2024 -- A popular asthma inhaler was discontinued on Jan. 1, and the business move has left families scrambling to find a replacement for their kids.Flovent was one of the most commonly prescribed drugs for childhood asthma, but.

Marketing 293

Marketing Drugs 293

Drug Channels

NOVEMBER 15, 2024

The authors outline the challenges that manufacturers face when integrating internal and external datasets to build market access and commercialization strategies. TThey argue that unified datasets and the addition of AI-driven analytics tools can improve decision making throughout a drug’s life cycle.

Marketing 98

Marketing International Drugs 98

BioPharma Drive: Drug Pricing

SEPTEMBER 26, 2024

The withdrawal comes as trial results indicate safety concerns with the drug, Oxbryta, which was first approved in the U.S.

Trials 280

Trials Marketing Drugs 280

BioPharma Drive: Drug Pricing

JULY 22, 2024

Private biotech company acquisitions are on their fastest pace in years, a trend some in the industry say is driven by the abundance of mature, but not yet public, drug startups.

Marketing 255

Marketing Drugs 255

Drugs.com

JANUARY 17, 2025

Food and Drug Administration has authorized the marketing of 20 ZYN nicotine pouch products. FRIDAY, Jan. 17, 2025 -- Following an extensive scientific review, the U.S. Nicotine pouches -- small synthetic fiber pouches containing nicotine -- are.

FDA Approval 130

FDA Approval Marketing FDA Production 130

Drug Patent Watch

APRIL 10, 2025

The team at Drug Patent Watch has done an incredible job of breaking down the key considerations for turning scientific discoveries into market power. "Just spent the morning digging into the world of pharmaceuticals and I'm blown away by the complexities of drafting effective drug patent applications.

Science 77

Science Marketing Drugs Pharmaceuticals 77

BioPharma Drive: Drug Pricing

MARCH 24, 2025

Understanding private sector breakthroughs, acquisitions and funding is critical in a volatile market.

Marketing 157

Marketing 157

Drug Patent Watch

FEBRUARY 27, 2025

Navigating the Complex World of Global Drug Patents: Strategies and Challenges Ahead As a pharmaceutical professional, you know how crucial it is to protect your innovative drug patents in the global market. But what can you do to protect your drug patent in global markets? Share your experiences and insights in the comments below!

Marketing 52

Marketing Drugs Regulations Pharmaceutical Companies 52

BioPharma Drive: Drug Pricing

APRIL 4, 2024

In the wake of a major trial failure, the company is withdrawing Relyvrio and cutting costs with a restructuring that involves laying off 70% of its employees.

Marketing 184

Marketing Trials Drugs 184

BioPharma Drive: Drug Pricing

OCTOBER 31, 2023

The pharma’s shot Abrysvo made over $300 million in sales during the first few months of its launch, and will be an important product to help offset declining COVID vaccine sales.

Vaccine 184

Vaccine Marketing Production 184

BioPharma Drive: Drug Pricing

FEBRUARY 9, 2024

Shortly after Kyverna priced one of the sector’s largest IPOs in recent years, Maag spoke with BioPharma Dive about what it takes to go public now.

Marketing 196

Marketing 196

BioPharma Drive: Drug Pricing

OCTOBER 29, 2024

New guidelines and the timing of COVID vaccinations impacted uptake of Abrysvo this year, according to a company executive.

Vaccine 167

Vaccine Marketing 167

BioPharma Drive: Drug Pricing

APRIL 7, 2025

Study results in a rare form of obesity could help the company expand use of Imcivree, which is approved for two genetically driven forms of excess weight.

Marketing 144

Marketing Drugs 144

BioPharma Drive: Drug Pricing

JULY 9, 2024

On Tuesday, regulators updated the public on their yearslong probe of PBM's business practices. The report faults PBMs for profiting at the expense of patients and independent pharmacists.

Marketing 144

Marketing Regulations Drugs 144

BioPharma Drive: Drug Pricing

NOVEMBER 5, 2024

Rallybio is headed into a mid-stage trial with enough cash to last it through 2026, but biotech's down market has made the company's journey difficult.

Marketing 130

Marketing Disease Trials 130

BioPharma Drive: Drug Pricing

APRIL 29, 2025

Deals with Hims & Hers, LifeMD and Ro following a court's dismissal of a lawsuit challenging the FDA's determination that Wegovy is no longer in shortage.

Marketing 157

Marketing FDA 157

Drug Patent Watch

JANUARY 30, 2025

Maximizing Patent Protection: Strategies for Pharmaceutical Marketers As a pharmaceutical marketer, you know how crucial it is to protect your patented drug's market share. In this post, we'll explore effective strategies for maximizing patent protection and exclusivity, ensuring your product remains a leader in the market.

Marketing 53

Marketing Drugs Production Pharmaceuticals 53

BioPharma Drive: Drug Pricing

DECEMBER 19, 2023

A decision by European regulators to revoke approvals for five generic versions of Biogen's multiple sclerosis medicine helps cement the drug's monopoly there through early 2025.

Marketing 167

Marketing Regulations Drugs 167

Drugs.com

FEBRUARY 21, 2025

FRIDAY, Feb. 21, 2025 -- New York Attorney General Letitia James filed a major lawsuit yesterday, accusing 13 e-cigarette companies of illegally selling flavored vapes and targeting young kids through deceptive marketing.The 192-page complaint.

Marketing 147

Marketing 147

BioPharma Drive: Drug Pricing

MAY 22, 2024

Direct-to-consumer platforms can offer consumers an online path to sourcing popular medications, but some therapeutic areas may be better suited for the business model.

Marketing 157

Marketing 157

BioPharma Drive: Drug Pricing

MARCH 26, 2025

Clearance of Vykat unlocks what analysts anticipate will be a lucrative market opportunity for Soleno Therapeutics.

FDA 326

FDA Marketing Drugs 326

BioPharma Drive: Drug Pricing

SEPTEMBER 12, 2024

The offerings by Bicara, Zenas and MBX give a glimpse into what industry insiders describe as a backlog of mature startups waiting for the right opportunity to test public markets.

Marketing 330

Marketing 330

BioPharma Drive: Drug Pricing

NOVEMBER 11, 2024

Negative drug results cost AbbVie billions of dollars in market value and convinced analysts that Bristol Myers had placed a better bet in buying Karuna Therapeutics.

Drugs 325

Drugs Marketing 325

BioPharma Drive: Drug Pricing

JULY 3, 2024

Multibillion-dollar buyouts from Bristol Myers Squibb and Gilead could yield new drugs for brain and liver diseases, while a new cell therapy may reach market.

FDA 317

FDA Therapies Disease Marketing 317

BioPharma Drive: Drug Pricing

JULY 11, 2024

Far behind companies like Novo and Eli Lilly, Pfizer hopes the version of the drug, danuglipron, that it’s chosen to advance can break into the ultra-lucrative market for weight-loss medicines.

Marketing 317

Marketing Drugs 317

BioPharma Drive: Drug Pricing

OCTOBER 13, 2023

Sales of Pfizer's antiviral Paxlovid and shot Comirnaty have been slower than it anticipated, while a shift to the commercial market for the antiviral has been delayed.

Production 343

Production Marketing 343

BioPharma Drive: Drug Pricing

MARCH 8, 2024

The results have led Amylyx to pause promotion of Relyvrio and potentially pull it from the market in the coming weeks, a major blow to the company and ALS patients.

Marketing 343

Marketing Drugs 343

Science Daily: Pharmacology News

AUGUST 16, 2024

With new medications on the market or in the works for Alzheimer's disease and other kinds of dementia, a new study suggests that getting the diagnosis needed to access these new treatments may depend on where you live.

Treatment 316

Treatment Disease Marketing 316

BioPharma Drive: Drug Pricing

DECEMBER 4, 2024

Results from the head-to-head study showed treatment with Zepbound resulted in 47% greater relative weight loss than Wegovy, a finding that could advantage Lilly in the companies’ market competition.

Drug Trials 313

Drug Trials Trials Treatment Marketing 313